Ly6E is a cell‑surface protein involved in tumor growth and immune evasion that is overexpressed across multiple solid tumor types, with limited expression in normal tissues. At AACR, researchers from Merck KGaA presented the preclinical characterization of M-7437, an anti-Ly6E ADC with a topoisomerase 1 (TOP1) inhibitor payload.
Shanghai Ailux Biotechnology Co. Ltd. and Ailux Inc. have presented preclinical data regarding the characterization of ALX-006, a 2+2 symmetric IgG1 PD‑1×VEGF bispecific antibody developed and designed for dual PD‑L1 and VEGF blockade as a cancer immunotherapeutic.
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has recently presented data for their AhR agonist EQ-504 for the potential treatment of immune-related diseases.
The combination of impaired epithelial barrier function, mucosal inflammation and elevated oxidative stress is determinant for the pathogenesis of ulcerative colitis (UC). NF-E2-related factor 2 (NRF2) is an important transcription factor for modulating antioxidant defenses, inhibiting inflammatory pathways and regenerating the epithelial barrier. Montai Therapeutics Inc. has developed a potent and selective NRF2 agonist compound, MTAI-1025, for the management of UC using its proprietary CONECTA platform.
T-cell engagers (TCEs) drive synthetic antitumor immunity by bypassing endogenous T-cell priming and directly inducing tumor cell killing. In prostate cancer, targeting prostate-restricted antigens such as STEAP2, combined with CD8-guided TCE formats that favor cytotoxic T-cell engagement, offers a strategy to reduce cytokine release while maintaining antitumor activity.
Researchers from Hangzhou DAC Biotechnology Co. Ltd. reported preclinical efficacy data for DXC-016, a next-generation, subcutaneously administered, dual-payload c-Met-targeting antibody-drug conjugate (ADC) derived from the DXA-016 anti-c-Met nanobody.
Tumor-associated calcium signal transducer 2 (TROP2) is a transmembrane glycoprotein involved in different signaling pathways that promote proliferation, migration and invasion of tumoral cells, and its overexpression is associated with poor prognosis in multiple cancer types. Astellas Pharma Inc. has developed a TROP2-targeting antibody-drug conjugate (ADC), ASP-2998, and recently presented preclinical data on the candidate.
Researchers from Genfleet Therapeutics (Shanghai) Co. Ltd. reported the preclinical profile of GFH-276, a molecular glue designed to function as a pan-RAS(ON) inhibitor.
Multidrug-resistant Klebsiella pneumoniae is a major health problem globally, with relevant infection-related mortality reported. Researchers from the Instituto de Salud Carlos III in Spain and their collaborators recently presented data regarding an outer membrane vesicle (OMV) vaccine for the management of K. pneumoniae infection, Kp-OMV4.
CDKs are central regulators of cell-cycle progression in cancer, with resistance to CDK4/6 inhibitors frequently converging on CDK2 activation through cyclin E upregulation or CCNE1 amplification, supporting CDK2 inhibition as a strategy to restore cell-cycle control. Researchers from Novartis AG have revealed the preclinical profile of ECI-830, an oral bioavailable, highly selective ATP-competitive CDK2 inhibitor.
RSS
